In particular, they clarified that loss of DGKα selectively ameliorates cisplatin sensitivity in cisplatin‐resistant ovarian cancer in a kinase‐dependent manner via its metabolic product, PA. This evidence concerns the gene DGKA and ovarian carcinoma.